Orthocell Ltd (ASX:OCC)'s Paul Anderson speaks to Proactive after announcing a breakthrough tissue engineering study, combining CelGro® with lymphatic and blood vessel cells to create functional lymphatic tissue, has been published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). The findings represent a substantial advance in the ex vivo fabrication of implantable lymphatic grafts and their use in novel surgical treatments for patients suffering from lymphedema.
Orthocell highlights potential for CelGro in treatment of lymphedema
Quick facts: Orthocell Ltd
Price: 0.51 AUD
Market Cap: $97.68 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE